IL-13 receptor α2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension
Cho WK, Lee CM, Kang MJ, Huang Y, Giordano FJ, Lee PJ, Trow TK, Homer RJ, Sessa WC, Elias JA, Lee CG. IL-13 receptor α2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2012, 304: l112-l124. PMID: 23125252, PMCID: PMC3543640, DOI: 10.1152/ajplung.00101.2012.Peer-Reviewed Original ResearchConceptsPulmonary hypertensionIL-13Human pulmonary artery smooth muscle cellsDevelopment of PHPulmonary artery smooth muscle cellsRight ventricle systolic pressurePathogenesis of PHArtery smooth muscle cellsExpression of ARG2Pulmonary arterial hypertensionPulmonary vascular remodelingVentricle systolic pressurePotential therapeutic targetIL-13 treatmentSmooth muscle cellsNull mutant miceArterial hypertensionEffector cytokinesMedial thickeningSystolic pressureHemodynamic changesPulmonary arterySmall-interfering RNAVascular remodelingArginase-2Targeted approaches to the treatment of pulmonary hypertension
Fares WH, Trow TK. Targeted approaches to the treatment of pulmonary hypertension. Therapeutic Advances In Respiratory Disease 2012, 6: 147-159. PMID: 22438264, DOI: 10.1177/1753465812441849.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionArterial hypertensionHigh-dose calcium channel blockersChest Physicians criteriaMultiple therapeutic optionsDurability of responseCalcium channel blockersTransplant evaluationPulmonary hypertensionOral therapyClose followPhysician's criteriaTherapeutic optionsChannel blockersEarly initiationAmerican CollegeHigh riskPatientsIncurable diseaseHypertensionEarly useStatus benefitsTreatmentDiseaseProgression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply